Myelofibrosis is diagnosed through a combination of bone marrow biopsy, genetic testing, blood work, and physical examination. No single test confirms it. Instead, doctors look for a pattern: abnormal bone marrow scarring, specific gene mutations, and supporting signs like an enlarged spleen or abnormal blood counts. A formal diagnosis requires meeting all three major criteria and at least one minor criterion, confirmed on two separate occasions.
Bone Marrow Biopsy: The Central Test
A bone marrow biopsy is the most important test in diagnosing myelofibrosis. A doctor uses a needle to extract a small core of bone (usually from the back of the hip) to examine under a microscope. The pathologist looks for two key features: abnormal overgrowth of the cells that produce platelets (megakaryocytes), and the degree of scarring (fibrosis) in the marrow tissue.
Fibrosis is graded on a scale from 0 to 3. Grade 0 means normal, with only scattered fibers and no cross-linking. Grade 1 shows a loose web of fibers with many intersections, especially around blood vessels. Grade 2 means dense, widespread fiber buildup with occasional patches of thicker collagen. Grade 3 is the most severe, with dense fibers interwoven with thick collagen bundles and often new bone formation within the marrow space. A diagnosis of overt (fully developed) myelofibrosis requires grade 2 or 3 fibrosis.
There is also an early form called prefibrotic myelofibrosis, where fibrosis is still below grade 2 but the marrow already shows abnormal megakaryocytes, increased cellularity, and a shift toward producing more white blood cells at the expense of red blood cells. This early form matters because it can look very similar to essential thrombocythemia (a related blood cancer marked by high platelet counts), but it carries a higher risk of progressing to full-blown myelofibrosis. Distinguishing the two requires careful examination of the bone marrow’s architecture and cell types.
One complication specific to myelofibrosis is the “dry tap,” where the aspiration needle fails to pull out any liquid marrow sample. This happens because the extensive scarring makes the marrow too stiff to extract. A dry tap itself is a strong clue that significant fibrosis is present. When it occurs, pathologists can sometimes prepare slides from the small amount of tissue left inside the needle, which can still provide useful diagnostic information alongside the solid biopsy core.
Genetic Testing for Driver Mutations
About 85% of people with primary myelofibrosis carry a mutation in one of three genes. The JAK2 mutation is by far the most common, found in roughly 60 to 66% of patients. The CALR mutation appears in about 12 to 20%, and the MPL mutation in about 5%. These are called “driver mutations” because they fuel the abnormal blood cell production that causes the disease.
Finding one of these mutations is a major diagnostic criterion. If none of the three is present, a person is considered “triple-negative,” which accounts for about 13 to 17% of cases. Triple-negative status doesn’t rule out the diagnosis, but it does make it harder to confirm and generally signals a less favorable prognosis, with a median survival around 56 months compared to 131 months for those with CALR mutations.
When all three driver mutations are absent, doctors look for other clonal markers, mutations in genes like ASXL1, EZH2, TET2, or SRSF2, that confirm the bone marrow changes are driven by a cancerous clone rather than a reactive process like infection or inflammation. The absence of any reactive cause for marrow fibrosis can also support the diagnosis.
Blood Tests and Peripheral Blood Smear
Routine blood work often provides the first clues. A complete blood count may show anemia (low red blood cells), elevated white blood cell counts above 11 × 10⁹/L, or abnormal platelet levels that can be either high or low depending on the stage. Lactate dehydrogenase (LDH), an enzyme that rises when cells are damaged or turning over rapidly, is typically elevated. An LDH level twice the upper limit of normal has about 94% specificity for distinguishing myelofibrosis from related conditions like essential thrombocythemia or polycythemia vera, though its sensitivity is only around 55%.
A peripheral blood smear, where a drop of blood is spread on a glass slide and examined under a microscope, reveals characteristic changes. Teardrop-shaped red blood cells (dacrocytes) are a hallmark finding. These cells become distorted as they squeeze through a scarred, stiffened bone marrow. Another classic finding is leukoerythroblastosis, where immature red blood cells and white blood cells that normally stay in the bone marrow spill into the bloodstream. This happens because the scarred marrow can no longer keep them contained, and blood cell production sometimes shifts to organs like the spleen and liver.
Physical Exam and Spleen Assessment
An enlarged spleen is one of the most recognizable signs of myelofibrosis and serves as a minor diagnostic criterion. Doctors assess this by pressing on the left upper abdomen to feel for the spleen’s edge below the rib cage. In a healthy person, the spleen isn’t palpable. In myelofibrosis, it can become massively enlarged as it takes over some of the bone marrow’s blood-producing duties.
About 38% of myelofibrosis patients have a spleen extending at least 10 centimeters below the left rib margin, and 23% have one extending more than 16 centimeters. If the spleen isn’t palpable in a standard position, the doctor may have you lie on your right side, which can shift it into a position where it’s easier to feel. When physical examination is uncertain, ultrasound, CT, or MRI can provide an objective measurement of spleen volume.
Ruling Out Other Conditions
Part of diagnosing myelofibrosis means confirming it isn’t something else. The formal criteria require that a patient does not meet the diagnostic criteria for chronic myeloid leukemia (which is defined by a specific gene fusion called BCR::ABL1), polycythemia vera, essential thrombocythemia, myelodysplastic syndrome, or other myeloid cancers. This is important because several of these conditions can cause marrow fibrosis that looks similar under the microscope.
Myelofibrosis can also develop as a complication of polycythemia vera or essential thrombocythemia, called post-PV or post-ET myelofibrosis. Diagnosing these secondary forms requires documentation of a prior PV or ET diagnosis plus evidence of new or worsening fibrosis. Other markers include a drop in hemoglobin of more than 20 g/L from baseline, loss of the need for treatments that were previously controlling high red blood cell counts, and the development of constitutional symptoms like unexplained fevers above 37.5°C, drenching night sweats, or more than 10% weight loss over six months.
How the Pieces Come Together
For overt primary myelofibrosis, you need to meet all three major criteria: grade 2 or 3 bone marrow fibrosis with abnormal megakaryocytes, the presence of a JAK2, CALR, or MPL mutation (or another clonal marker), and exclusion of other myeloid cancers. On top of that, at least one minor criterion must be present: anemia, elevated white blood cell count, palpable spleen enlargement, elevated LDH, or leukoerythroblastosis. Each of these minor findings must be confirmed on two separate occasions to avoid a diagnosis based on a temporary lab fluctuation.
For the prefibrotic (early) form, the same structure applies, but the bone marrow shows less than grade 2 fibrosis along with increased cellularity and granulocyte proliferation. Catching this early stage is valuable because it identifies patients who are at risk of progression before severe scarring develops, allowing earlier monitoring and, when appropriate, earlier treatment decisions.